Effect of the Bufeinashen Pills on the Treatment of Chronic Obstructive Pulmonary Disease in Rats and Its Impacts on ERK 1/2 in Pulmonary Tissue
Objective To investigate the intervention effect of Bufeinashen pills(BFNSP)on a rat model of chronic obstructive pulmonary disease(COPD)and its influence on the expression of extracellular regulated protein kinase 1/2(ERK 1/2)in lung tissue.Methods Thirty-eight SPF SD male rats were randomly divided into control group(6 rats),COPD group(8 rats),BFNSP-H group(6 rats),BFNSP-M group(6 rats),and BFNSP-L group(6 rats),and dexamethasone group(6 rats).Except for the control group,COPD rat models were prepared by cigarette smoke combined with intratracheal instillation of lipopolysaccharide(LPS).The high,medium,and low dose BFNSP and dexamethasone groups were treated with corresponding drugs via gav-age for 8 weeks,while the control and COPD groups were given equal volumes of normal saline by gavage.The general condition,HE staining of lung tissue,and levels of interleukin-1β(IL-1β)in bronchoalveolar lavage flu-id(BALF)of rats in each group were compared to evaluate the intervention effect of BFNSP on COPD rats.The protein levels of P-ERK 1/2 in lung tissue were detected by Western blot,and the mRNA expression of ERK 1/2 was detected by RT-qPCR.Results After modeling,the model rats showed symptoms consistent with clin-ical observations,such as cough,dyspnea,poor mental and activity status.HE staining showed inflammatory cell infiltration and alveolar cavity shrinkage.Compared with the COPD group,the levels of IL-1β in BALF of the BFNSP and dexamethasone groups were significantly lower(P all<0.05),and the expression levels of ERK 1/2 mRNA and protein in lung tissue were significantly decreased(P all<0.05).Conclusion BFNSP can ef-fectively inhibit lung tissue inflammation in COPD rats and suppress the expression of ERK 1/2,thereby delay-ing the progression of COPD.
万方数据
